ESC 365 - SAIT - Specific Active immunotherapy (SAIT) against PCSK9 is safe and lowers circulating LDL-C in humans

ESC Premium Access

SAIT - Specific Active immunotherapy (SAIT) against PCSK9 is safe and lowers circulating LDL-C in humans

Session: Late Breaking Pharmacological Science

Topic: Lipid-Lowering Agents

Speaker: Associate Professor M. Bauer (Vienna, AT)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Associate Professor Martin Bauer

Medical University of Vienna, Vienna (Austria)

1 presentation

0 follower

12 more presentations in this session

Panel discussants.

CLARIFY - First-line anti-ischemic agents use and long-term clinical outcomes in stable coronary artery disease

Speaker: Doctor E. Sorbets (Paris, FR)

Panel discussion.

FOURIER - Efficacy of PCSK9 inhibition with evolocumab in patients with Metabolic Syndrome

Speaker: Professor P. Deedwania (Fresno, US)

Panel discussion.

Access the full session

Late Breaking Pharmacological Science

Speakers: Associate Professor M. Bauer, Doctor E. Sorbets, Professor P. Deedwania

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources